1-methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
The present invention is directed to nicotinamide derivatives, and their use in treating lipoprotein abnormalities, alone or in combination with a statin.
1. A method of increasing HDL-cholesterol levels in a subject in need thereof, comprising the steps of:
administering to said subject a therapeutically effective amount of a first pharmaceutical composition comprising a 1-methylnicotinamide salt; and
administering to said subject a therapeutically effective amount of a second pharmaceutical composition comprising a statin selected from the group consisting of simvastatin, atorvastatin and a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein said subject has low HDL-cholesterol levels before administering of said first and said second pharmaceutical compositions.
3. The method of claim 1 , wherein said 1-methylnicotinamide salt is selected from the group consisting of 1-methylnicotinamide chloride, 1-methylnicotinamide benzoate, 1-methylnicotinamide salicylate, 1-methylnicotinamide acetate, 1-methylnicotinamide citrate, and 1-methylnicotinamide lactate.
4. The method of claim 1 , wherein said first and said second pharmaceutical compositions are co-administered to said subject.
5. The method of claim 1 , wherein said first and said second pharmaceutical compositions are administered sequentially to said subject.
6. The method of claim 1 , wherein each of said first and said second pharmaceutical compositions is independently administered orally, parenterally, buccally, sublingually or topically.
7. The method of claim 6 , wherein each of said first and said second pharmaceutical compositions is administered orally.
8. The method of claim 7 , wherein at least one of said first and said second pharmaceutical compositions is administered in a tablet or capsule.
9. The method of claim 7 , wherein at least one of said first and said second pharmaceutical compositions is in controlled release or sustained release form.
10. The method of claim 1 , wherein each of said first and said second pharmaceutical compositions is independently administered from one to five times per day to said subject.
11. The method of claim 10 , wherein each of said first and said second pharmaceutical compositions is independently administered from one to two times per day to said subject.
12. The method of claim 1 , wherein each of said first and said second pharmaceutical compositions is independently formulated using one or more pharmaceutically acceptable carriers or excipients.
13. The method of claim 1 , wherein said subject is a mammal.
14. The method of claim 13 , wherein said subject is human.
15. A method of decreasing triglyceride levels in a subject in need thereof, comprising the steps of:
administering to said subject a therapeutically effective amount of a first pharmaceutical composition comprising a 1-methylnicotinamide salt; and
administering to said subject a therapeutically effective amount of a second pharmaceutical composition comprising a statin selected from the group consisting of simvastatin, atorvastatin and a pharmaceutically acceptable salt thereof.
16. The method of claim 15 , wherein said 1-methylnicotinamide salt is selected from the group consisting of 1-methylnicotinamide chloride, 1-methylnicotinamide benzoate, 1-methylnicotinamide salicylate, 1-methylnicotinamide acetate, 1-methylnicotinamide citrate and 1-methylnicotinamide lactate.
17. The method of claim 15 , wherein said first and said second pharmaceutical compositions are co-administered to said subject.
18. The method of claim 15 , wherein said first and said second pharmaceutical compositions are administered sequentially to said subject.
19. The method of claim 15 , wherein each of said first and said second pharmaceutical compositions is independently administered orally, parenterally, buccally, sublingually or topically.
20. The method of claim 19 , wherein each of said first and said second pharmaceutical compositions is administered orally.
21. The method of claim 20 , wherein at least one of said first and said second pharmaceutical compositions is administered in a tablet or capsule.
22. The method of claim 20 , wherein at least one of said first and said second pharmaceutical composition is in controlled release or sustained release form.
23. The method of claim 15 , wherein each of said first and said second pharmaceutical compositions is independently administered from one to five times per day.
24. The method of claim 23 , wherein each of said first and said second pharmaceutical compositions is independently administered from one to two times per day.
25. The method of claim 15 , wherein each of said first and said second pharmaceutical compositions is formulated using one or more pharmaceutically acceptable carriers or excipients.
26. The method of claim 15 , wherein said subject is a mammal.
27. The method of claim 26 , wherein said subject is human.